Thank you for your continuous support. We regret to inform you that the deadline for announcing the winner of the Best Paper Award has been postponed to 30 June 2027.
The editorial office would like to apologize for any inconvenience caused. If you have any questions, please do not hesitate to contact us.
The IJMS Best Paper Award is granted annually to highlight publications of high quality, scientific significance, and extensive influence. The evaluation committee members choose six articles of exceptional quality that were published in the journal the year before the previous year and announce them online by the end of June.
The Prize:
– Three research articles and three reviews will be selected.
– Each winner will receive a certificate and a free voucher for article processing fees valid for one year.
Eligibility and Requirements
– All papers published in the IJMS will be eligible (both regular and Special Issue submissions).
Photodynamic therapy (PDT) is a two-stage treatment that implies the use of light energy, oxygen, and light-activated compounds (photosensitizers) to elicit cancerous and precancerous cell death after light activation (phototoxicity). The biophysical...
Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer. Although great efforts have been made by clinicians and researchers, no significant improvement in survival has been achieved since the Stupp protocol became the stan...
The use of non-coding RNAs (ncRNAs) as drug targets is being researched due to their discovery and their role in disease. Targeting ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), is an attractive approach for treating variou...
The pandemic of coronavirus disease 2019 (COVID-19) has been the foremost modern global public health challenge. The airway is the primary target in severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection, with substantial cel...
The advancement of exosome studies has positioned engineered exosomes as crucial biomaterials for the development of advanced drug delivery systems. This study focuses on developing a hybrid exosome system by fusing mesenchymal stem cells (MSCs) exos...
HDAC11 is a class IV histone deacylase with no crystal structure reported so far. The catalytic domain of HDAC11 shares low sequence identity with other HDAC isoforms, which makes conventional homology modeling less reliable. AlphaFold is a machine l...
Maurizio Battino
Antonio Pisani
Manlio Ferrarini
Salah Eddine Stiriba
João Pedro Silva
José L. Quiles
